Literature DB >> 30135499

Genome-wide mRNA expression analysis of peripheral blood from patients with obsessive-compulsive disorder.

Yuqing Song1, Yansong Liu2, Panpan Wu3, Fuquan Zhang4, Guoqiang Wang5.   

Abstract

The onset of obsessive-compulsive disorder (OCD) involves the interaction of heritability and environment. The aim of this study is to identify the global messenger RNA (mRNA) expressed in peripheral blood from 30 patients with OCD and 30 paired healthy controls. We generated whole-genome gene expression profiles of peripheral blood mononuclear cells (PBMCs) from all the subjects using microarrays. The expression of the top 10 mRNAs was verified by real-time quantitative PCR (qRT-PCR) analysis. We also performed an enrichment analysis of the gene ontology (GO) and Kyoto Encyclopaedia of Genes and Genomes (KEGG) annotations of the differentially expressed mRNAs. We identified 51 mRNAs that were significantly differentially expressed between the subjects with OCD and the controls (fold change ≥1.5; false discovery rate <0.05); 45 mRNAs were down-regulated and 6 mRNAs were up-regulated. The qRT-PCR analysis of 10 selected genes showed that they were all up-regulated, which was opposite to the results obtained from the microarrays. The GO and KEGG enrichment analysis showed that ribosomal pathway was the most enriched pathway among the differentially expressed mRNAs. Our findings support the idea that altered genome expression profiles may underlie the development of OCD.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30135499      PMCID: PMC6105577          DOI: 10.1038/s41598-018-30624-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


Introduction

Obsessive-compulsive disorder (OCD) is characterized by recurrent intrusive thoughts or images (obsessions) and/or ritualized behaviours (compulsions) that cause marked distress and impairment to a person[1]. About 1–3% of the general population suffers from OCD[2-5] and the symptoms appear before age 25 years in about two-thirds of affected persons, with the mean age of onset about 20 years[2,4]. Both environmental and genetic factors are deemed to play important roles in the aetiology of OCD and genetic factors account for about 45–65% of variance in OCD if the disorder occurs in childhood[6]. Despite the great progress made in understanding the pathogenesis of the disorder, the genetic causes of OCD remain elusive. This may be because the aetiology of OCD is complex and probably related with multiple independent and interacting genetic factors. The completion of the Human Genome Project and the development of genome-wide screening have made microarray technology an important tool to study genetic effects on the aetiology of psychiatric disorders[7]. Previous studies have found genes in blood and brain tissues share similar expression patterns[8,9], and it is easier to measure gene expression in blood because it can be obtained with minimal invasiveness. Microarray approaches have been widely used to investigate neuropsychiatric disorders such as schizophrenia[10], bipolar disorder[11], and major depressive disorder (MDD)[12]. In addition, microarray data have been used to find novel genes and pathways that may be related with the aetiology of psychiatric disorders[7]. However, to our knowledge, microarrays have not been applied to investigate gene expression in the peripheral blood of OCD patients. In this study, we aimed to detect genes (mRNAs) that were differentially expressed between patients with OCD and healthy controls using microarray technology. We also performed an enrichment analysis of the gene ontology (GO) terms and Kyoto Encyclopaedia of Genes and Genomes (KEGG) pathways assigned to the genes to investigate the functions of the differentially expressed mRNAs.

Results

Differentially expressed mRNAs

We used microarrays in a genome-wide scan of mRNAs from peripheral blood mononuclear cells (PBMCs) of 30 patients with OCD and 30 paired healthy controls. We detected a total of 51 differentially expressed mRNAs with fold change ≥1.5 and false discovery rate <0.05; 45 were down-regulated and 6 were up-regulated (Table 1, Fig. 1). The hierarchical cluster analysis showed that the samples separated into distinct patient and control groups (Fig. 2).
Table 1

All the differentially expressed genes (Benjamini-Hochberg adjusted p-value < 0.05) detected between the OCD patients and healthy controls with current NCBI Entrez gene records.

Gene SymbolGene NameChromosomeregulationp ValueFold changeFDR
1RPL27ribosomal protein L27chr17down6.91E-070.5827629480.003187
2RPS18ribosomal protein S18chr6down5.72E-070.6107880040.003187
3RPL26ribosomal protein L26chr17down4.42E-060.424817140.003546
4COMMD6COMM domain containing 6chr13down2.76E-060.4272942990.003546
5RPL34ribosomal protein L34chr4down3.24E-060.4458848090.003546
6RPS7ribosomal protein S7chr2down3.24E-060.4586317490.003546
7RPL31ribosomal protein L31chr2down4.42E-060.5014109420.003546
8RPL39ribosomal protein L39chrXdown3.79E-060.5396141890.003546
9TOMM7translocase of outer mitochondrial membrane 7 homolog (yeast)chr7down3.79E-060.5421382270.003546
10EEF1B2eukaryotic translation elongation factor 1 beta 2chr2down4.42E-060.5566889070.003546
11RPS15Aribosomal protein S15achr16down2.35E-060.5620207560.003546
12RGS4regulator of G-protein signaling 4chr1down3.79E-060.5664139390.003546
13RPL35ribosomal protein L35chr9down2.35E-060.590629580.003546
14RPS29ribosomal protein S29chr14down2.76E-060.5963786920.003546
15SNRPD2small nuclear ribonucleoprotein D2 polypeptide 16.5 kDachr19down2.35E-060.6314751090.003546
16RPL35Aribosomal protein L35achr3down1.42E-060.6481756220.003546
17RPL6ribosomal protein L6chr12down3.79E-060.6527100160.003546
18RPS24ribosomal protein S24chr10down5.14E-060.4506041380.003796
19RPL17ribosomal protein L17chr18down5.97E-060.5130454760.003935
20RPL23ribosomal protein L23chr17down6.92E-060.4957247750.004254
21RPS17ribosomal protein S17chr15down6.92E-060.5229416990.004254
22RPL41ribosomal protein L41chr12down1.06E-050.4830012020.004773
23RPL11ribosomal protein L11chr1down1.06E-050.6649637570.004773
24RPS21ribosomal protein S21chr20down1.22E-050.6569730820.005226
25PFDN5prefoldin subunit 5chr12down1.40E-050.5238570140.005855
26RPL21ribosomal protein L21chr13down1.82E-050.6033597860.006472
27RPL7ribosomal protein L7chr8down2.08E-050.4969594210.006716
28RPS27ribosomal protein S27chr1down2.37E-050.5252599840.006716
29COX7Ccytochrome c oxidase subunit VIIcchr5down2.37E-050.6316209330.006716
30NDUFA4NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 4, 9 kDachr7down2.08E-050.6619014040.006716
31UQCRBubiquinol-cytochrome c reductase binding proteinchr8down2.69E-050.513081110.006985
32TAS2R46taste receptor, type 2, member 46chr12up2.69E-051.7558543990.006985
33CD52CD52 moleculechr1down2.69E-050.6302998470.006985
34OCR1ovarian cancer-related protein 1chr1up3.05E-051.7217991540.007602
35RPS3Aribosomal protein S3Achr4down3.90E-050.4968053640.008573
36RPL9ribosomal protein L9chr4down5.59E-050.5546583370.010214
37NDUFA1NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 1, 7.5 kDachrXdown5.59E-050.6518533570.010214
38XRCC6BP1XRCC6 binding protein 1chr12down8.86E-050.6216417410.012966
39HINT1histidine triad nucleotide binding protein 1chr5down9.90E-050.6593651250.013141
40KLRB1killer cell lectin-like receptor subfamily B, member 1chr12down0.0001530.6400294770.015753
41MANSC1MANSC domain containing 1chr12up0.0001531.5520733680.015753
42TAS2R30taste receptor, type 2, member 30chr12up0.0001531.5075790760.015753
43RPL22L1ribosomal protein L22-like 1chr3down0.000380.5985401110.024601
44COMMD8COMM domain containing 8chr4down0.000380.6261336590.024601
45NDUFA5NADH dehydrogenase (ubiquinone) 1 alpha subcomplex, 5, 13 kDachr7down0.000380.6273597580.024601
46GZMAgranzyme A (granzyme 1, cytotoxic T-lymphocyte-associated serine esterase 3)chr5down0.0006080.6565863120.029848
47RPS27Lribosomal protein S27-likechr15down0.0006080.6626139450.029848
48MRPS28mitochondrial ribosomal protein S28chr8down0.0006670.6562635510.030893
49FBXL13F-box and leucine-rich repeat protein 13chr7up0.0007981.5456022010.033757
50ZNF721zinc finger protein 721chr4down0.0011310.4839700740.040059
51CACNB4calcium channel, voltage-dependent, beta 4 subunitchr2up0.0011311.6286453690.040059
Figure 1

Volcano plot of changes in the whole-genome gene expression profiles of peripheral blood mononuclear cells between OCD patients and healthy controls. A total of 51 significantly differentially expressed mRNAs with fold change ≥1.5 and Bonferroni-adjusted p-value < 0.05 were detected. Blue dots indicate the 45 down-regulated genes, red dots indicate the 6 up-regulated genes. The horizontal green line is the negative logarithm of the Bonferroni-adjusted p-value threshold.

Figure 2

Heatmap of the top 100 differentially expressed genes that can distinguish OCD patients and healthy controls obtained by hierarchical cluster analysis.

All the differentially expressed genes (Benjamini-Hochberg adjusted p-value < 0.05) detected between the OCD patients and healthy controls with current NCBI Entrez gene records. Volcano plot of changes in the whole-genome gene expression profiles of peripheral blood mononuclear cells between OCD patients and healthy controls. A total of 51 significantly differentially expressed mRNAs with fold change ≥1.5 and Bonferroni-adjusted p-value < 0.05 were detected. Blue dots indicate the 45 down-regulated genes, red dots indicate the 6 up-regulated genes. The horizontal green line is the negative logarithm of the Bonferroni-adjusted p-value threshold. Heatmap of the top 100 differentially expressed genes that can distinguish OCD patients and healthy controls obtained by hierarchical cluster analysis.

Functional annotation

The GO functional enrichment analysis revealed 23 of the 51 significantly differentially expressed mRNAs were enriched in ribosomal protein terms, including cellular protein metabolic process, endocrine pancreas development, viral transcription, viral infectious cycle, viral reproduction, gene expression, translation, and RNA binding. The genes encoding NDUFA4 (NADH dehydrogenase (ubiquinone) 1alpha subcomplex), NDUFA5, and NDUFA1 were significantly enriched in mitochondrial electron transport and NADH to ubiquinone, and the genes encoding NDUFA4, COX7C (cytochrome c oxidase subunit VIIc), and UQCRB (ubiquinol-cytochrome c reductase binding protein) were significantly enriched in hydrogen ion transmembrane transport. The KEGG pathway analysis of the 51 significantly differentially expressed mRNAs also identified 23 mRNAs that were enriched in ribosome; NDUFA4, NDUFA5, COX7C, NDUFA1, and UQCRB, which were significantly enriched in Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, and non-alcoholic fatty liver disease, and COX7C, CACNB4 (calcium channel, voltage-dependent, beta 4 subunit), and UQCRB, which were significantly enriched in cardiac muscle contraction (Table 2).
Table 2

Functional categories and biological function annotations based on gene ontology (GO) terms and KEGG pathways.

CategoryFunctions Annotationp-ValueMolecules
KEGG analysisRibosome8.15E-31RPL35A, RPL17, RPL35, RPS15A, RPS27L, RPL22L1, RPL39, RPS7, RPS27, RPS29, RPL41, RPL7, RPL23, RPS17, RPS3A, RPL31, RPL6, RPL21, RPL9, RPL34, RPL11, RPS21, RPS24
Oxidative phosphorylation0.003482NDUFA4, NDUFA5, COX7C, NDUFA1, UQCRB
Parkinson’s disease0.004403NDUFA4, NDUFA5, COX7C, NDUFA1, UQCRB
Non-alcoholic fatty liver disease (NAFLD)0.005477NDUFA4, NDUFA5, COX7C, NDUFA1, UQCRB
Alzheimer’s disease0.00796NDUFA4, NDUFA5, COX7C, NDUFA1, UQCRB
Huntington’s disease0.012589NDUFA4, NDUFA5, COX7C, NDUFA1, UQCRB
Cardiac muscle contraction0.04943COX7C, CACNB4, UQCRB
Go analysisRibosome2.57E-29RPL35A, RPL17, RPL35, RPS15A, RPS27L, RPL22L1, RPL39, RPS7, RPS27, RPS29, RPL41, RPL7, RPL23, RPS17, RPS3A, RPL31, RPL6, RPL21, RPL9, RPL34, RPL11, RPS21, RPS24
mitochondrial electron transport, NADH to ubiquinone0.006979NDUFA4, NDUFA5, NDUFA1
hydrogen ion transmembrane transport0.010652NDUFA4, COX7C, UQCRB
mitochondrial electron transport, cytochrome c to oxygen0.050016NDUFA4, COX7C

Significant biological pathways with two or more differentially expressed mRNAs representing each function are shown.

Functional categories and biological function annotations based on gene ontology (GO) terms and KEGG pathways. Significant biological pathways with two or more differentially expressed mRNAs representing each function are shown.

Real-time quantitative PCR (qRT-PCR) validation

To validate the results of the microarray analysis, we chose 10 differently expressed mRNA transcripts for validation by qRT-PCR, namely, RPS3A, RPL34, RPS24, RPL23, RPS7, RPL41, RPL7, RPL26, ZNF721, and COMMD6. The qRT-PCR results showed that RPL34 was down-regulated consistent with the microarray analysis, whereas RPS3A, RPS24, RPL23, RPS7, RPL41, RPL7, and RPL26 were up-regulated (Table 3). ZNF721 and COMMD6 were not found to be differently expressed between OCD and healthy controls by qRT-PCR (Table 3).
Table 3

The mRNA expression levels in OCD patients and healthy controls by qRT-PCR.

Gene SymbolOCD (n = 26)Healthy controls (n = 26)RegulationP valueFold changeFDR
1RPS75.33 ± 3.361.20 ± 1.11up2.576E-074.4572.58E-06
2RPS3A4.23 ± 3.980.84 ± 0.70up8.292E-055.0660.0004
3RPL340.14 ± 0.110.33 ± 0.26down0.0010.4220.002
4RPS2430.01 ± 26.289.42 ± 14.64up0.0013.1880.002
5RPL2313.64 ± 10.986.53 ± 9.00up0.0142.090.018
6RPL415.60 ± 5.331.92 ± 3.00up0.0032.9130.004
7RPL7186.69 ± 251.2423.61 ± 26.98up0.0027.9090.003
8RPL267.22 ± 7.881.45 ± 2.05up0.0014.9710.002
9ZNF7210.73 ± 0.710.77 ± 0.810.8580.9510.858
10COMMD60.45 ± 0.480.61 ± 0.580.2990.7460.332
The mRNA expression levels in OCD patients and healthy controls by qRT-PCR.

Discussion

To the best of our knowledge, this is the first study to reveal differentially expressed genes between patients with OCD and healthy controls using mRNA microarray technology. We found 45 mRNAs that were down-regulated and 6 mRNAs that were up-regulated in patients with OCD. Previous studies have indicated that important genes involved in the pathophysiology of OCD were related to serotonin, dopamine, and glutamate systems[13-15]; however, we did not detect these genes in the present study. These discrepancies may be explained by the different research methods that were used. In previous studies, candidate gene approaches were used to explore OCD-related genes[13-15], whereas we used microarrays to detect genes related to OCD[16]. The GO and KEGG analyses revealed 23 differentially expressed mRNAs that were enriched in terms and pathways related with ribosomal proteins (RPs). Ribosomes are subcellular organelles composed of two different subunits[17], and each subunit contains various numbers of ribosomal RNAs (rRNAs) and RPs. Large 60S ribosomal subunits assemble with small 40S subunits to form 80S ribosomes. In mammals, the 80S ribosomal nucleoprotein complex contains 4 rRNAs and about 80 proteins, with more than 150 associated proteins and about 70 small nucleolar RNAs[18]. The small 40S subunit mediates the interactions between tRNAs and mRNA and selects the correct tRNA for the decoding centre. The large 60S subunit harbours the peptidyl transferase centre and provides the exit tunnel for the growing nascent polypeptide chain. Ribosomes function in translating mRNAs into proteins and translation is tightly depended on the ribosome proteins (RPs)[19]. RPs are highly conserved, so quantitative deficiencies result in reduced protein synthesis[20], which can affect a range of pathological processes such as cancer[21], genetic diseases[22], and viral infection[23]. RP-encoding genes are widely dispersed. Both human sex chromosomes and the autosomes (all but chromosomes 7 and 21) carry one or more RP genes[20]. Disturbance in translational homeostasis was shown to be involved in the pathogenesis of neurodegenerative disorders[24,25]. For example, a decline in the amount of rRNA was found to be associated with the progression of Alzheimer’s disease[26]. Ribosomes may not be involved only in severe psychiatric disorders. For example, the copy numbers of ribosomal genes were shown to increase in schizophrenia and decrease in autism[27]. Mutations in the RP-encoding gene RPL10 were reported in people with autism[28], but another study did not find changes in RPL10 expression associated with autism[29]. Changes in ribosomes have also been associated with depression. The transcriptional activity of ribosomal DNA was diminished in the argyrophilic nucleolar organizer region of brain tissue of patients with MDD, which suggested hypoactivity of neurons in MDD[30], and another study revealed over-expressed RPs in the hippocampus of a mouse model of MDD[31]. In the current study, we found the mRNAs that encoded RPs were down-regulated, which may decrease the number of ribosomes and subsequently reduce protein synthesis. The down-regulation of mRNAs encoding some RPs may only reduce protein synthesis, which is not as drastic as the complete mutation or deletion of an RP gene. This, combined with other unknown factors, potentially could produce the symptoms of OCD. Members of the zinc finger protein (ZNF) family have DNA- and RNA-binding motifs and the amino acids are folded into a single structural unit around a zinc atom[32]. ZNF proteins have a wide-range of functions, including transcription and DNA recognition[33]. ZNF804A has been identified as one of the most compelling risk genes associated with psychiatric disorders[34,35]. In the current study, we found that the ZNF721 mRNA was down-regulated in the OCD patients. COMMD (copper metabolism domain containing) proteins (also known as MURR1) were discovered about 10 years ago, and 10 COMMD proteins are known so far. They are involved in, for example, copper homeostasis, regulating transcription factor NF-κB (nuclear factor κB), and cell proliferation[36]. COMMD6, a ubiquitously expressed small soluble protein and endogenous inhibitor of NF-κB, binds DNA and activates transcription[37,38]. Activation of NF-κB has been associated with some neurodegeneration diseases as consequences of the neurotoxic role of NF-κB[39]. The down-regulation of COMMD6 or the action of another NF-κB inhibitor NFKBIA may increase the activation of NF-κB, which might impair the function of the hippocampus in individuals with OCD. NADH dehydrogenase (ubiquinone) 1 alpha subcomplex (NDUFA4) is the 14th subunit of cytochrome c oxidase. NDUFA4L2 inhibits complex I of oxidative phosphorylation, which is the final oxygen-accepting enzyme complex of the mitochondrial respiratory chain, to mediate a shift to glycolysis in growing cells and cancer tissues[40]. The over-expression of NDUFA4 seen in lung cancer cells is in contrast to its down-regulation in Alzheimer’s disease. In a previous genome-wide study, NDUFA4 was found to be associated with Alzheimer’s disease and was identified as a potential biomarker of the disease[41]. Ubiquinol cytochrome c reductase binding protein (UQCRB) is important for mitochondrial complex III stability, electron transport, cellular oxygen sensing, and angiogenesis. NDUFA, COX7C, and UQCRB are involved in the mitochondrial respiratory chain, and all three were down-regulated in the OCD patients. However, there is limited knowledge about the relationship between mitochondrial dysfunction and OCD. The genes encoding type-2 bitter-taste receptors (TAS2R30 and TAS2R46) were up-regulated in OCD. TAS2Rs are expressed widely outside the brain, but their relationship to OCD is not known. CACNB4 is one of the voltage-gated calcium channel beta subunits, which was recently found to function in neuronal excitability and gene transcription[42]. CACNB4 was over-expressed in schizophrenia and was associated with depressing the calcium currents that drive spine formation and stabilization, and increased CACNB4 expression was found to drive small spine loss[43]. We consider the up-regulation of CACNB4 detected in our study may be related with the pathogenesis of OCD. Several limitations in our study should be noted. First, the sample size was relatively small, which may have reduced the statistical power of the comparison of gene expression between the OCD and healthy control groups. There were inconsistencies in the direction of gene alterations between the microarray analysis and the qRT-PCR validation, likely because different samples were used for validation and the patients were at different stages of the disorder and under different treatment regimes. In conclusion, we detected altered gene expression patterns in patients with OCD and highlighted the role of RP genes in the pathogenesis of OCD.

Materials and Methods

Participant profiles

This study was conducted in the Wuxi Mental Health Centre of Nanjing Medical University, Wuxi, Jiangsu Province, China. Thirty patients with OCD and 30 sex- and age-paired healthy controls were recruited. There were 20 males and 10 females in both groups. The mean age was 28.8 ± 12.0 years (range 15–60 years) and 28.8 ± 11.1 years (range 17–56 years) for the patient and the control groups respectively. The diagnosis of OCD was confirmed using the structured clinical interview for DSM-IV disorders (SCID). Patients with schizophrenia, MDD, comorbid axis I disorder, or with a history of neurological disease were excluded. Healthy controls who were free from any psychiatric illness or major medical condition were recruited from the local community. This study was approved by the human ethics committee of the Wuxi Mental Health Centre of Nanjing Medical University. Written informed consent was provided by each participant. All study procedures were in accordance with the Helsinki Declaration of 1975.

Blood sample collection and PBMC isolation

Peripheral blood was collected in 10-ml vacutainer tubes containing EDTA and immediately stored at 4 °C. Whole blood was processed within 2 h of collection. Ficoll density gradient centrifugation was used to separate the peripheral blood mononuclear cells (PBMCs). Briefly, saline diluted blood was layered over Ficoll, then centrifuged to separate red blood cells, PBMCs, and plasma. The PBMCs were gently and entirely sucked up from the layer of Ficoll and transferred to a new tube, which was washed twice.

Total RNA isolation

Total RNA was extracted from the PBMCs using TRIzol reagent (Invitrogen, USA) according to the manufacturer’s instructions and quantified using a NanoDrop ND-2000 (Thermo Scientific). RNA integrity (RIN) was assessed using an Agilent Bioanalyzer 2100 (Agilent Technologies). The mean (SD) RIN for all the samples was 9.29 (0.48). The 28S to 18S rRNA ratio was 2.79 (0.35) and the RIN was ≥7. For 28S:18S a RIN value ≥0.7 was considered to be within the range of acceptable RNA quality according to the manufacturer’s instructions.

mRNA microarray, labelling, hybridization, and scanning

Total RNA was labelled with a mRNA Complete Labelling and Hyb Kit (Agilent Technologies) and hybridized on a Human lncRNA Microarray 4.04 × 180 K (Agilent Technologies). The microarray contains 30,656 probes for human mRNA, all of which were derived from authoritative databases, including RefSeq Build, Ensemble Release, GenBank, and Unigene Build. Total RNA (200 ng each) was reverse transcribed to double-strand cDNA, then synthesized into cRNA and labelled with cyanine-3-CTP. The labelled cRNAs were hybridized to the microarray. After washing, the arrays were scanned using an Agilent Microarray Scanner (G2505C, Agilent Technologies).

Validation by qRT-PCR

Total RNA was isolated from PBMCs from another 26 pairs of OCD and healthy controls using TRIzol reagent (Invitrogen) with on-column DNase I treatment as described by the manufacturer. cDNA was synthesized using a High Capacity RNA-to-cDNA Kit (Invitrogen) according to the manufacturer’s instructions. The qRT–PCRs were performed using the primers listed in Table 4 and SYBR® Select Master Mix (Invitrogen) on a 7900HT real-time PCR machine (Applied Biosystems, USA) with the following cycles: 2 min at 50 °C, 2 min at 95 °C, then 40 cycles of 15 s at 95 °C, 60 s at 60 °C, followed by a standard dissociation protocol to ensure that each amplicon was a single product. All quantifications were normalized to ACTB. The qRT–PCRs were performed in triplicate for each independent sample.
Table 4

Primers for the differently expressed mRNAs used in the qRT-PCRs.

Gene SymbolPrimerPrimer sequences
1RPS71-Forwardatgttcagttcgagcgcc
1-Reversettcgcgtactagccggac
2RPS3A2-Forwardtggcatggatcttacccg
2-Reversegatttggcggacctgttg
3RPL343-Forwardtgacaggatcaagcgtgc
3-Reversettgcagcatttgctgagg
4RPS244-Forwardcgccatcatgaacgacac
4-Reversegccagttgtcttgccacc
5RPL235-Forwardacagacttcccgctgctg
5-Reverseaatcatgcaatgctgcca
6RPL416-Forwardgaggccacaggagcagaa
6-Reverseagaggaccaacatgggca
7RPL77-Forwardgcgaaggaatttcgcaga
7-Reversettgccagcttttcttgcc
8RPL268-Forwardcttccgaccgaagcaaga
8-Reversectggggtgaatgcctacg
9ZNF7219-Forwardtggacggtacacagccct
9-Reversecaaaggctctgccacgat
10COMMD610-Forwardggcaatcagaagagtgaggc
10-Reversetcgtctttccaactctgcg
Primers for the differently expressed mRNAs used in the qRT-PCRs.

Data analysis

Agilent Feature Extraction software (version 10.7.1.1; Agilent Technologies) was used to analyse the array images to obtain the raw data. GeneSpring (GX v11.5.1 software package; Agilent Technologies) was employed to analyse the raw data. The raw data were first normalized with the quantile algorithm, followed by differential expression analysis using a student t-test. The probes that had at least 1 out of 2 conditions and had 75% flags in “P” were chosen for further data analysis. Differentially expressed genes were identified based on fold change as well as the p-value calculated with the student t-test. The threshold set for up- and down-regulated genes was fold change ≥ 1.5 and false discovery rate ≤ 0.05. The expression levels of mRNAs between the OCD patients and healthy controls were analysed using the Mann-Whitney U test. To correlate the differentially expressed mRNAs with biological processes, we annotated the mRNAs with GO terms and KEGG pathways (http://www.genome.ad.jp/kegg/) to determine their potential roles. Then, we performed a hierarchical clustering analysis to display the distinguishable gene expression patterns between the OCD and healthy groups. The lower the p-value, the more significant the correlation; the recommended p-value cut-off was 0.05.
  43 in total

1.  Combining mapping and arraying: An approach to candidate gene identification.

Authors:  M L Wayne; L M McIntyre
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-01       Impact factor: 11.205

2.  Expression analysis of a novel mRNA variant of the schizophrenia risk gene ZNF804A.

Authors:  Takeya Okada; Ryota Hashimoto; Hidenaga Yamamori; Satomi Umeda-Yano; Yuka Yasuda; Kazutaka Ohi; Motoyuki Fukumoto; Keiko Ikemoto; Yasuto Kunii; Hiroaki Tomita; Akira Ito; Masatoshi Takeda
Journal:  Schizophr Res       Date:  2012-09-23       Impact factor: 4.939

Review 3.  How might ZNF804A variants influence risk for schizophrenia and bipolar disorder? A literature review, synthesis, and bioinformatic analysis.

Authors:  Jonathan L Hess; Stephen J Glatt
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2013-10-04       Impact factor: 3.568

Review 4.  Regulation of Mammalian 13-Subunit Cytochrome c Oxidase and Binding of other Proteins: Role of NDUFA4.

Authors:  Bernhard Kadenbach
Journal:  Trends Endocrinol Metab       Date:  2017-10-05       Impact factor: 12.015

5.  Symptoms of obsessive-compulsive disorder.

Authors:  J F Leckman; D E Grice; J Boardman; H Zhang; A Vitale; C Bondi; J Alsobrook; B S Peterson; D J Cohen; S A Rasmussen; W K Goodman; C J McDougle; D L Pauls
Journal:  Am J Psychiatry       Date:  1997-07       Impact factor: 18.112

6.  Stress dynamically regulates behavior and glutamatergic gene expression in hippocampus by opening a window of epigenetic plasticity.

Authors:  Carla Nasca; Danielle Zelli; Benedetta Bigio; Sonia Piccinin; Sergio Scaccianoce; Robert Nisticò; Bruce S McEwen
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-16       Impact factor: 11.205

7.  Family-based association studies support a sexually dimorphic effect of COMT and MAOA on genetic susceptibility to obsessive-compulsive disorder.

Authors:  M Karayiorgou; C Sobin; M L Blundell; B L Galke; L Malinova; P Goldberg; J Ott; J A Gogos
Journal:  Biol Psychiatry       Date:  1999-05-01       Impact factor: 13.382

8.  Analysis of whole genome biomarker expression in blood and brain.

Authors:  Brandi Rollins; Maureen V Martin; Ling Morgan; Marquis P Vawter
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2010-06-05       Impact factor: 3.568

9.  Prevalence of DSM-IV psychiatric disorder in the French elderly population.

Authors:  K Ritchie; S Artero; I Beluche; M-L Ancelin; A Mann; A-M Dupuy; A Malafosse; J-P Boulenger
Journal:  Br J Psychiatry       Date:  2004-02       Impact factor: 9.319

10.  Investigating the role of dopaminergic and serotonergic candidate genes in obsessive-compulsive disorder.

Authors:  Sîan M J Hemmings; Craig J Kinnear; Dana J H Niehaus; Johanna C Moolman-Smook; Christine Lochner; James A Knowles; Valerie A Corfield; Dan J Stein
Journal:  Eur Neuropsychopharmacol       Date:  2003-03       Impact factor: 4.600

View more
  4 in total

1.  Predictive Potential of Circulating Ube2h mRNA as an E2 Ubiquitin-Conjugating Enzyme for Diagnosis or Treatment of Alzheimer's Disease.

Authors:  Key-Hwan Lim; Jae-Yeol Joo
Journal:  Int J Mol Sci       Date:  2020-05-11       Impact factor: 5.923

2.  Brain areas involved with obsessive-compulsive disorder present different DNA methylation modulation.

Authors:  Kátia Cristina de Oliveira; Caroline Camilo; Vinícius Daguano Gastaldi; Arthur Sant'Anna Feltrin; Bianca Cristina Garcia Lisboa; Vanessa de Jesus Rodrigues de Paula; Ariane Cristine Moretto; Beny Lafer; Marcelo Queiroz Hoexter; Euripedes Constantino Miguel; Mariana Maschietto; Helena Brentani
Journal:  BMC Genom Data       Date:  2021-10-30

Review 3.  Genetics of obsessive-compulsive disorder.

Authors:  Behrang Mahjani; Katharina Bey; Julia Boberg; Christie Burton
Journal:  Psychol Med       Date:  2021-05-25       Impact factor: 7.723

4.  Generalized and social anxiety disorder interactomes show distinctive overlaps with striosome and matrix interactomes.

Authors:  Kalyani B Karunakaran; Satoko Amemori; N Balakrishnan; Madhavi K Ganapathiraju; Ken-Ichi Amemori
Journal:  Sci Rep       Date:  2021-09-15       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.